Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a clinical-stage biotechnology company whose news flow centers on the development of its Decoy bacterial immunotherapy platform for cancer and viral infections. The company’s updates frequently highlight progress in its clinical program for Decoy20, its lead candidate, as well as financing transactions and corporate developments disclosed through press releases and SEC filings.
Investors following INDP news can expect detailed reports on the INDP-D101 clinical trial, including the monotherapy evaluation of Decoy20 and the combination arm with the PD-1 checkpoint inhibitor tislelizumab in advanced solid tumors. Recent announcements have described safety lead-in results, individual patient responses such as a partial response in a urothelial cancer patient, and instances of stable disease in combination cohorts, along with commentary from company leadership on trial strategy and next steps.
Indaptus also issues news about scientific presentations and conference participation, where its team discusses how the Decoy platform activates innate and adaptive immune cells and its potential to support allogeneic cell therapies by enhancing donor cell potency. In addition, the company regularly reports quarterly financial results, outlining research and development spending on its Phase 1/1b/2 program, general and administrative expenses, cash runway expectations, and the impact of financings such as private placements of convertible notes, equity offerings and preferred stock transactions.
For market participants, the INDP news stream offers insight into clinical milestones, safety and early efficacy signals, intellectual property developments, capital structure changes, reverse stock split implementation, and board and management updates. Monitoring this page provides a consolidated view of how Indaptus is advancing its Decoy platform and managing the operational and financial aspects of its clinical-stage business.
Indaptus Therapeutics (Nasdaq: INDP) will present a corporate overview at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET, by CEO Jeffrey A. Meckler. A live webcast will be available on the company's investors section of its website, with a replay accessible for 90 days afterward.
Indaptus specializes in immunotherapy, leveraging patented technology involving non-pathogenic bacteria to activate immune cells for anti-tumor and anti-viral responses. The company has received FDA clearance for a Phase 1 trial of Decoy20 targeting advanced solid tumors.
Indaptus Therapeutics recently announced that the FDA has cleared its IND application for a Phase 1 clinical trial of Decoy20 in patients with advanced solid tumors. Scheduled to start in the second half of 2022, the trial aims to evaluate the safety and preliminary efficacy of Decoy20, which targets tumors resistant to current therapies. Decoy20's unique technology mobilizes both innate and adaptive immune responses without inducing significant side effects. The trial will utilize a dose escalation design, and the therapy could potentially treat various cancers, including pancreatic and colorectal carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET. A live webcast will be available on the company's website and will be archived for 90 days.
Indaptus focuses on immunotherapy, utilizing patented technology that activates innate and adaptive immune cells to combat tumors and viral infections, demonstrating potential in preclinical models against chronic HBV and HIV.
Indaptus Therapeutics has submitted an Investigational New Drug (IND) application for Decoy20, aimed at treating solid tumors, with a Phase 1 clinical trial expected to start in 2022. The submission signifies a crucial step in the development of Decoy20, a dual Toll-like receptor (TLR) agonist that shows promise in activating immune responses against cancers. Financially, the company reported a loss per share of $0.41 for Q1 2022, along with increased R&D and administrative expenses, totaling $3.4 million. Cash reserves decreased to $36.2 million from $39.1 million in Q4 2021.
Indaptus Therapeutics (Nasdaq: INDP) announced that Dr. Michael J. Newman will present at the 2nd Annual Chronic HBV Drug Development Summit from April 25-27, 2022, in Boston, MA. The presentation is titled Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine and will occur on April 27, 2022, at 12:00 PM ET. The summit aims to advance antiviral and immunotherapy development for chronic hepatitis B virus (HBV) treatment.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the Maxim Group 2022 Virtual Growth Conference on March 28, 2022, at 9:00 a.m. ET. The presentation will be pre-recorded, and an audio webcast will be accessible for 90 days via Indaptus' website. The company focuses on immunotherapy solutions leveraging patented technology involving non-pathogenic bacteria to activate immune responses for anti-tumor and anti-viral applications. Indaptus has successfully manufactured its lead candidate, Decoy20, and has completed various IND enabling studies.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported its financial results for Q4 and the year ending December 31, 2021. R&D expenses rose 150% to $1 million for Q4, while total R&D costs decreased 4% to $2.5 million for the year. G&A expenses surged 475% to $2.3 million in Q4, totaling $5.2 million annually, mainly due to payroll and public company costs post-Decoy merger. The company recorded a loss per share of $1.89 and had $39.1 million in cash as of year-end. Net cash used in operating activities ballooned to $11.3 million. Financing activities generated $48.3 million in 2021.
Indaptus Therapeutics (Nasdaq: INDP) announces that Dr. Michael J. Newman will present at the 3rd Annual STING & TLR-Targeting Therapies Summit from March 22-24, 2022. The presentation titled “Eradication of Established Tumors with Induction of Innate & Adaptive Immunological Memory” is scheduled for March 24 at 11:30 AM ET. Dr. Newman will also participate in a panel discussion on the best modalities for PRR-pathway targeting later that day at 1:30 PM ET. Indaptus focuses on innovative immunotherapy solutions with a patented technology that combines non-pathogenic bacteria to enhance immune response.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the 34th Annual ROTH Conference on March 14-15, 2022. An audio webcast of this presentation is available here and on the company's website, where it will be archived for 90 days. Indaptus focuses on immunotherapy, employing a multi-targeted approach for anti-tumor and anti-viral responses.
Indaptus Therapeutics (Nasdaq: INDP) announced CEO Jeffrey Meckler will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10 at 7:00 a.m. ET. The presentation will be pre-recorded and available via an audio webcast on the company's website, archived for approximately 90 days. Indaptus focuses on immunotherapy, using patented technology to activate immune responses for anti-tumor and anti-viral treatments. Their lead candidate, Decoy20, has undergone successful GMP manufacturing and is progressing with IND enabling studies.